Beatriz Brito, Thomas W Price, Cátia V Rocha, Manuel Bañobre-López, Graeme J Stasiuk, Juan Gallo
{"title":"Pt(IV)功能化聚丙烯酸包覆氧化铁磁性纳米颗粒作为氧化还原反应性癌症治疗药物。","authors":"Beatriz Brito, Thomas W Price, Cátia V Rocha, Manuel Bañobre-López, Graeme J Stasiuk, Juan Gallo","doi":"10.1039/d5tb01007a","DOIUrl":null,"url":null,"abstract":"<p><p>Iron oxide nanoparticles represent a class of nanomaterials with unique physicochemical properties and high potential for theranostic applications. Herein, we functionalised polyacrylic acid (PAA)-coated iron oxide nanoparticles with a chemotherapeutic Pt(IV) prodrug, to prepare Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanostructures that act as <i>T</i><sub>2</sub> MR theranostics with redox- (and thus TME-) responsive therapeutic properties. The synthesis of Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanoparticles was optimised to yield nanoparticles with appropriate hydrodynamic diameter and Pt/Fe ratio. The Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanoparticles displayed promising magnetic and relaxometric properties, showing a higher relaxivity than commercially available NP-based MRI agent Resovist®. Cell internalisation studies in 2D and 3D cell models demonstrated that the nanomaterials accumulated in cancer cells after only 6 h of incubation at a concentration that allowed for contrast enhancement in MRI. Cell viability studies showed that Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanoparticles were 2.5 times more effective than the Pt(IV) prodrug in inducing apoptosis (IC<sub>50</sub> = 156 μM <i>vs.</i> 379 μM) in 2D models, while in 3D models, they were found to be as effective as active drug cisplatin. These results show the potential of these versatile Pt(IV)-functionalised PAA-coated iron oxide nanostructures as redox responsive MR theranostics for cancer therapy.</p>","PeriodicalId":94089,"journal":{"name":"Journal of materials chemistry. B","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227113/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pt(IV)-functionalised polyacrylic acid-coated iron oxide magnetic nanoparticles as redox-responsive cancer theranostics.\",\"authors\":\"Beatriz Brito, Thomas W Price, Cátia V Rocha, Manuel Bañobre-López, Graeme J Stasiuk, Juan Gallo\",\"doi\":\"10.1039/d5tb01007a\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Iron oxide nanoparticles represent a class of nanomaterials with unique physicochemical properties and high potential for theranostic applications. Herein, we functionalised polyacrylic acid (PAA)-coated iron oxide nanoparticles with a chemotherapeutic Pt(IV) prodrug, to prepare Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanostructures that act as <i>T</i><sub>2</sub> MR theranostics with redox- (and thus TME-) responsive therapeutic properties. The synthesis of Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanoparticles was optimised to yield nanoparticles with appropriate hydrodynamic diameter and Pt/Fe ratio. The Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanoparticles displayed promising magnetic and relaxometric properties, showing a higher relaxivity than commercially available NP-based MRI agent Resovist®. Cell internalisation studies in 2D and 3D cell models demonstrated that the nanomaterials accumulated in cancer cells after only 6 h of incubation at a concentration that allowed for contrast enhancement in MRI. Cell viability studies showed that Fe<sub>3</sub>O<sub>4</sub>@PAA-Pt(IV) nanoparticles were 2.5 times more effective than the Pt(IV) prodrug in inducing apoptosis (IC<sub>50</sub> = 156 μM <i>vs.</i> 379 μM) in 2D models, while in 3D models, they were found to be as effective as active drug cisplatin. These results show the potential of these versatile Pt(IV)-functionalised PAA-coated iron oxide nanostructures as redox responsive MR theranostics for cancer therapy.</p>\",\"PeriodicalId\":94089,\"journal\":{\"name\":\"Journal of materials chemistry. B\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227113/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of materials chemistry. B\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1039/d5tb01007a\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of materials chemistry. B","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/d5tb01007a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
氧化铁纳米颗粒是一类具有独特物理化学性质的纳米材料,具有很高的治疗应用潜力。在此,我们将聚丙烯酸(PAA)包覆的氧化铁纳米颗粒与化疗前药Pt(IV)功能化,制备Fe3O4@PAA-Pt(IV)纳米结构,作为T2 MR治疗剂,具有氧化还原(从而具有TME-)响应治疗特性。对Fe3O4@PAA-Pt(IV)纳米颗粒的合成进行了优化,得到了合适的水动力直径和Pt/Fe比的纳米颗粒。Fe3O4@PAA-Pt(IV)纳米颗粒显示出良好的磁性和弛豫特性,比市售的基于np的MRI剂Resovist®具有更高的弛豫度。在2D和3D细胞模型中进行的细胞内化研究表明,纳米材料仅在培养6小时后就在癌细胞中积累,其浓度允许在MRI中增强造影剂。细胞活力研究表明,Fe3O4@PAA-Pt(IV)纳米颗粒在2D模型中诱导细胞凋亡的效果是Pt(IV)前药的2.5倍(IC50 = 156 μM vs. 379 μM),而在3D模型中,其效果与活性药物顺铂相当。这些结果显示了这些多功能Pt(IV)功能化paa涂层氧化铁纳米结构作为氧化还原反应性磁共振治疗癌症的潜力。
Pt(IV)-functionalised polyacrylic acid-coated iron oxide magnetic nanoparticles as redox-responsive cancer theranostics.
Iron oxide nanoparticles represent a class of nanomaterials with unique physicochemical properties and high potential for theranostic applications. Herein, we functionalised polyacrylic acid (PAA)-coated iron oxide nanoparticles with a chemotherapeutic Pt(IV) prodrug, to prepare Fe3O4@PAA-Pt(IV) nanostructures that act as T2 MR theranostics with redox- (and thus TME-) responsive therapeutic properties. The synthesis of Fe3O4@PAA-Pt(IV) nanoparticles was optimised to yield nanoparticles with appropriate hydrodynamic diameter and Pt/Fe ratio. The Fe3O4@PAA-Pt(IV) nanoparticles displayed promising magnetic and relaxometric properties, showing a higher relaxivity than commercially available NP-based MRI agent Resovist®. Cell internalisation studies in 2D and 3D cell models demonstrated that the nanomaterials accumulated in cancer cells after only 6 h of incubation at a concentration that allowed for contrast enhancement in MRI. Cell viability studies showed that Fe3O4@PAA-Pt(IV) nanoparticles were 2.5 times more effective than the Pt(IV) prodrug in inducing apoptosis (IC50 = 156 μM vs. 379 μM) in 2D models, while in 3D models, they were found to be as effective as active drug cisplatin. These results show the potential of these versatile Pt(IV)-functionalised PAA-coated iron oxide nanostructures as redox responsive MR theranostics for cancer therapy.